Higher haematocrit levels: do they improve patient outcomes, and are they cost effective?
Collins
A J
AJ
Keane
W F
WF
D000740:Anemia / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use; D006400:Hematocrit; D006801:Humans; D007501:Iron / Q000008:administration & dosage; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000401:mortality; D011994:Recombinant Proteins; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron